Infanrix-Ipv

Pertussis Toxoid, Pertactin, the active ingredient in Infanrix-Ipv, is a vaccine presented as a vaccine formulation for intramuscular use. It prevents pertussis (whooping cough) in infants and children.\n\nGNH India supplies Infanrix-Ipv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and health‑care providers worldwide, ensuring quality‑controlled distribution and regulatory compliance.

Infanrix-Ipv is a pertussis vaccine used to protect against Bordetella pertussis infection.\n\n- Pertussis (whooping cough): provides active immunity that reduces the risk of infection and severe disease in infants and children.\n- Infant immunisation schedule: contributes to the recommended primary series for early childhood protection.\n- Community health programs: supports herd immunity to lower overall pertussis transmission in the population.

Common Side Effects:\n- Injection site pain: mild to moderate discomfort at the injection site.\n- Redness or swelling: localized erythema or edema.\n- Fever: low‑grade temperature rise within 24‑48 hours.\n- Irritability or fussiness: especially in infants.\n- Loss of appetite: temporary decrease in feeding.\n\nSerious or Rare Side Effects:\n- Anaphylaxis: severe allergic reaction requiring immediate medical attention.\n- Seizures: rare neurologic events post‑vaccination.\n- High fever: temperature above 40°C that persists.\n- Prolonged crying: excessive crying lasting more than three hours.\n- Hypotonic‑hyporesponsive episode: transient loss of muscle tone in infants.

Infanrix-Ipv should be administered only after evaluating the individual's health status.\n\n- Allergy screening: avoid in persons with known hypersensitivity to any vaccine component.\n- Acute illness: postpone vaccination if the patient has a moderate or severe febrile illness.\n- Immunocompromised patients: assess risk‑benefit, as response may be reduced.\n- Concomitant vaccines: follow recommended intervals when co‑administering with live vaccines.\n- Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccination with Infanrix-Ipv may be influenced by other medical products.\n\nMajor Interactions (Avoid):\n- Live attenuated vaccines: avoid administration within four weeks before or after Infanrix-Ipv.\n- Immunoglobulin therapy: concurrent use may diminish vaccine‑induced immunity.\n\nModerate Interactions (Monitor Closely):\n- Antipyretics before vaccination: may blunt antibody response; use only after vaccination if needed.\n- Systemic corticosteroids: may reduce immunogenicity, monitor antibody levels.\n- Blood products: transfusions within two weeks may interfere with vaccine effectiveness.